Cytomegalovirus Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

The Cytomegalovirus (CMV) Treatment Market is anticipated to register a CAGR of 6.1% during the forecast period.

COVID-19 significantly impacted the cytomegalovirus treatment market during the pandemic period. The patients with cytomegalovirus infection were more prone to COVID-19 than the patients without the infection, thereby impacting the demand for treatment during the COVID-19 outbreak. For instance, the article published in the Journal of Medical Virology published in October 2021 mentioned that patients with cytomegalic virus infection might have presented with more severe COVID-19 upon admission to healthcare centers than those without the infections. Such a high risk of cytomegalovirus is expected to have a notable impact on the market's growth over the forecast period. However, the reduction of COVID-19 cases in the post-pandemic period is expected to contribute to the growth of the market owing to the rising focus on the development of advanced treatments for cytomegalovirus, thereby boosting the market growth over the forecast period.

The rising prevalence of CMV retinitis and congenital CMV infection, extending the application range of CMV treatment, increasing initiatives for creating awareness regarding treatments and diagnosis of these conditions, and increasing clinical trial studies for the development of new drugs are likely to be the factors responsible for the growth of this market.

For instance, as per the CDC data updated in May 2022, in the United States, around 150 infants are born with cytomegalovirus infections every year, and a few of them have long-term health issues. CMV infection in infants generates an attenuated interferon response associated with a similar infection in the adult. As per the same source, cytomegalovirus infection and the risk of reactivation of cytomegalovirus infection have been reported during pregnancy and can also lead to congenital CMV infection. Thus, the rising disease burden is expected to drive the demand for effective treatment options, thereby contributing to the market's growth.

In addition, the increasing prevalence of viral infections among AIDS patients due to weakened immune systems is expected to drive the demand for cytomegalovirus drugs. For instance, according to the WHO updates from November 2022, an estimated 38.4 million people were living with HIV, with 36.7 million adults and 1.7 million children affected with HIV in 2021. Since one of the most common Opportunistic Infections (OIs) documented in people with human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) is Cytomegalovirus (CMV), the demand for cytomegalovirus treatment is anticipated to grow over the coming years.

Furthermore, the rising product approvals and product developments by various key market players are also expected to drive the market's growth in the forecast period. For instance, in May 2022, Hologic, Inc. announced that the US FDA approved its Aptima CMV Quant assay to quantify the viral load of Cytomegalovirus (CMV) in patients with solid organ or stem cell transplants. Similarly, in October 2021, Moderna, Inc. announced the first participant had been dosed in the Phase III pivotal registration study of mRNA-1647, the company’s Cytomegalovirus (CMV) vaccine candidate. This study is known as CMVictory.

However, adverse effects and risks related to cytomegalovirus drugs may hamper the demand for the Cytomegalovirus (CMV) Treatment Market.

Cytomegalovirus Treatment Market Trends

Stem Cell Transplantation Segment is Expected to Hold the Substantial Share in the Market During the Forecast Period

Stem cell transplantation is poised to benefit from the inclusion of new cell types, providing substantial opportunities for companies to reinforce their market position. As a result, the number of companies involved in cell therapy development has increased tremendously over the past years. Rising funding from the government and private organizations to support stem cell therapy clinical trials, the introduction of effective guidelines for stem cell therapy manufacturing, and the proven effectiveness of products are expected to be some of the primary growth drivers for the market segment.

As per the Springer study published in July 2021, CMV cell-mediated immunity assays have the potential to be used as an adjunctive test to develop an individualized management plan by identifying the patients who develop immune reconstitution. Maribavir and adoptive T-cell therapy are promising new therapies for treating CMV infections. CMV vaccine trials for prevention are also underway. Thus, the segment is expected to witness robust growth over the forecast period.

Moreover, the rising product approvals by various regulatory authorities are also expected to contribute to the market's growth. For instance, in September 2022, Health Canada authorized (Notice of Compliance) Takeda's LIVTENCITY (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies and individuals who have had a solid organ transplant or a hematopoietic stem cell transplant.

North America is Expected to Hold Notable Share of the Market Over the Forecast Period

North America is projected to hold a significant share of the global market throughout the forecast period. The increasing incidences of cytomegalovirus infections, increasing awareness among consumers, and the presence of key market players are some of the factors expected to play a crucial role in the market's growth in this region.

For instance, the article published by NINDS in July 2022 mentioned that CMV infected about 50% to 80% of adults by the age of 40 and is one of the most congenital infections in the United States annually. Similarly, the CMV Canada data published in June 2021, mentioned that one in 200 Canadian infants is infected with CMV during pregnancy. The report also mentioned that 1 in 5 congenital CMV had a permanent disability such as hearing loss or developmental delay. On the other hand, the BMC article published in September 2022, mentioned that seroprevalence of CMV infection in pregnant women in Mexico was higher in those aged 30 to 30 years (86.5%) than those aged less than 20 years in 2021. Such an increased incidence of CMV among the North American population is expected to contribute to the higher demand for effective treatment, thereby driving the growth of the market.

Likewise, the rising product approvals to provide safe and effective treatments to patients are also expected to drive the market's growth during the forecast period. For instance, in November 2021, Takeda pharmaceutical received FDA approval for the product, Maribavir for the treatment of adults and pediatric patients aged 12 years or older with post-transplant cytomegalovirus infection/disease that is refractory to treatment.

Hence, the rising prevalence of CMV infections, the presence of key market players, and frequent product developments are expected to drive the market's growth over the forecast period in this region.

Cytomegalovirus Treatment Market Competitor Analysis

The Cytomegalovirus Treatment Market is observed to be competitive owing to the presence of local as well as global players. The major players include companies such as F. Hoffmann-La Roche Ltd, Fresenius Kabi Canada, Genentech, Inc., Gilead Sciences, Merck & Co., Inc, Teva Canada Limited, and Thermo Fisher Scientific.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.